Navigation Links
NYSE Amex Required Update
Date:8/29/2011

ANNAPOLIS, Md., Aug. 29, 2011 /PRNewswire/ -- PharmAthene, Inc. (NYSE Amex: PIP), a biodefense company developing medical countermeasures against biological and chemical threats, announced today that in view of the relatively large increase in the price of its stock at the end of the trading day on August 25, 2011, the NYSE Amex has contacted the Company in accordance with its usual practice.  It is the Company's policy not to comment on market rumors. However, in compliance with  NYSE Amex listing requirements and at the Exchange's direction, the Company confirms that at the time of this release, it has not received from the Court of Chancery of Delaware a decision relating to the pending litigation with Siga Technologies, Inc. or any additional specific information relating to the timing thereof.

Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed may constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "believe"; "anticipate"; "intend"; "plan"; "expect"; "estimate"; "could"; "may"; "should"; or similar statements are forward-looking statements. PharmAthene disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risk associated with the reliability of the results of the studies relating to human safety and possible adverse effects resulting from the administration of the Company's product candidates, unexpected funding delays and/or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Form 10-K under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, the timing of the Court's decision and outcome of the case are uncertain. The Court could rule against the Company and find that SIGA did not breach. Furthermore, even if the Court rules in our favor, there can be no assurance that the associated remedy will be significant. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at http://www.pharmathene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
2. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
3. Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
4. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2011 Financial Results
5. BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
6. Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar
7. MIT research update: New way to store suns heat
8. Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
9. China-Biotics Provides Update
10. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
11. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 02, 2016 , ... ... -operated small businesses in federally funded research and development is welcome news for ... optics and photonics . , As part of the National Defense Authorization Act ...
(Date:12/2/2016)... ... December 02, 2016 , ... In anticipation of ... lumbar disc production, company President, Jake Lubinski will be traveling to Switzerland from ... disc in Bern, Lucerne, and Zurich to discuss the benefits of a viscoelastic ...
(Date:12/2/2016)... , Dec. 2, 2016 CytRx Corporation ... development company specializing in oncology, today announced the appointment ... sarcoma surgeon, industry consultant, and private healthcare investor, to ... a healthcare leader with clinical and strategic experience at ... CytRx,s Chairman and CEO. "As one of the world,s ...
(Date:12/2/2016)... (PRWEB) , ... December 01, 2016 , ... ... pneumatic tube systems for North American hospitals, will present its chain-of-custody solution for ... and Exhibition in Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a ...
Breaking Biology Technology:
(Date:11/15/2016)... 15, 2016  Synthetic Biologics, Inc. (NYSE MKT: ... on the gut microbiome, today announced the pricing ... of its common stock and warrants to purchase ... price to the public of $1.00 per share ... from the offering, excluding the proceeds, if any ...
(Date:6/27/2016)... Research and Markets has announced the addition of the ... The report forecasts the biometrics ... a CAGR of 12.28% during the period 2016-2020. ... with inputs from industry experts. The report covers the market landscape ... includes a discussion of the key vendors operating in this market. ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
Breaking Biology News(10 mins):